دورية أكاديمية
Interleukin-15 cytokine checkpoints in natural killer cell anti-tumor immunity.
| العنوان: | Interleukin-15 cytokine checkpoints in natural killer cell anti-tumor immunity. |
|---|---|
| المؤلفون: | Sudholz H; Department of Biochemistry and Molecular Biology, Biomedicine Discovery Institute, Monash University, Clayton, Victoria 3800, Australia., Delconte RB; Immunology Program, Memorial Sloan Kettering Cancer Center, New York 10065, USA., Huntington ND; Department of Biochemistry and Molecular Biology, Biomedicine Discovery Institute, Monash University, Clayton, Victoria 3800, Australia; oNKo-Innate Pty Ltd, Moonee Ponds, Victoria 3039, Australia. Electronic address: nicholas.huntington@monash.edu. |
| المصدر: | Current opinion in immunology [Curr Opin Immunol] 2023 Oct; Vol. 84, pp. 102364. Date of Electronic Publication: 2023 Jul 12. |
| نوع المنشور: | Journal Article; Review |
| اللغة: | English |
| بيانات الدورية: | Publisher: Elsevier Country of Publication: England NLM ID: 8900118 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1879-0372 (Electronic) Linking ISSN: 09527915 NLM ISO Abbreviation: Curr Opin Immunol Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: 1999- : London : Elsevier Original Publication: Philadelphia, PA, USA : Current Science, c1988- |
| مستخلص: | Over recent years, the use of immune checkpoint inhibitors (ICI) has progressed to first and second-line treatments in several cancer types, transforming patient outcomes. While these treatments target T cell checkpoints, such as PD-1, LAG3 and CTLA-4, their efficacy can be compromised through adaptive resistance whereby tumors acquire mutations in genes regulating neoantigen presentation by MHC-I [93]. ICI-responsive tumor types such as advanced metastatic melanoma typically have a high mutational burden and immune infiltration; however, most patients still do not benefit from ICI monotherapy for a number of reasons [94]. This highlights the need for novel immunotherapy strategies that evoke the immune control of tumor cells with low neoantigen/MHC-I expression, overcome immune suppressive tumor microenvironments and promote tumor inflammation. In this regard, targeting natural killer (NK) cells may offer a solution to some of these bottlenecks. Competing Interests: Declaration of Competing Interest N.D.H. is a founder and shareholder in oNKo-Innate. N.D.H serves on an advisory board for Bristol Myers Squibb. N.D.H. is an inventor of patents relating to this work. All other authors declare no competing interests. (Copyright © 2023 Elsevier Ltd. All rights reserved.) |
| تواريخ الأحداث: | Date Created: 20230714 Latest Revision: 20230930 |
| رمز التحديث: | 20240628 |
| DOI: | 10.1016/j.coi.2023.102364 |
| PMID: | 37451129 |
| قاعدة البيانات: | MEDLINE |
Full Text via ClinicalKey 
Full Text Finder كن أول من يترك تعليقا!